ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1056

Clinical Characterization of a Cohort of Patient with Sclerotic-type Chronic Graft-versus-host Disease with Fascial/joint Involvement

Cristina Hidalgo1, Concepción Roman2, Olga Compan3, Sonia Pastor Navarro4, Marta Ibañez5, Belen Miguel6, Maria Dolores Sanchez7, Lucía Pantoja8, Carlos Montilla5 and Lucía López-Corral2, 1Hospital Universitario Salamanca, Salamanca, Spain, 2Universitary Hospital, Salamanca, Spain, 3Complejo asistencial Universitario de Palencia, Carbajosa De La Sagrada, Spain, 4Hospital Universitario de Salamanca, Salamanca, Spain, 5Complejo asistencial Universitario de Salamanca, Salamanca, Spain, 6University Hospital, Salamanca, Spain, 7Universitary Hospital, Valladolid, Spain, 8Complejo Asistencial Hospital General, Segovia, Spain

Meeting: ACR Convergence 2022

Keywords: Disability, Fibrosing syndromes, Scleroderma

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Graft-versus-host disease (GVHD) is the most frequent complication after allogeneic hematopoietic cell transplantation (allo-HCT). Its chronic form usually involves a multisystemic syndrome that reflects a complex immune response with varying degrees of inflammation, immune dysregulation and fibrosis, responsible for the characteristic clinical manifestations of the disease. Joint and fascial involvement represents one of the most complicated areas, often unnoticed or poorly assessed, which negatively impacts the physical function and quality of life of these patients. The aims is to describe the clinical-biological characteristics of 82 patients with chronic sclerotic-type GVHD with joint/fascial involvement evaluated in a multidisciplinary consultation.

Methods: Descriptive and retrospective observational study to describe the initial and follow-up presence of musculoskeletal manifestations diagnostic of cGVHD in a cohort of 118 patients included in the database. The clinical characteristics of the 82 patients with an established diagnosis of sclerotic cGVHD with fascial/articular involvement are detailed (Figure 1). Demographic variables are collected along with baseline disease and transplant-related characteristics and in a systematic way the assessment according to diagnostic criteria of the North American National Institute of Health (NIH) 2015 highlighting: range of motion (ROM) and photographic range of motion (P-ROM) scales. Descriptive and frequency statistical analysis was performed using the SPSS version 25 statistical package.

Results: Eighty-two (69.4%%) patients met defined diagnostic criteria for sclerotic GVHD with musculoskeletal involvement during follow-up. Fifty-three (64.6%) men, with a mean age of 51 years (range 7-76), Acute myeloid leukemia was the reason for transplantation in 28 (34.1%)%) followed by non-Hodgkin’s lymphoma in 17 (20.7%). In 49 (59.8%) patients it was performed from a related donor and with reduced intensity conditioning in 48 (58.5%) (Table 1). The mean time from transplantation to the first visit was 22 months (range 4 -176). Table 2 details the clinical manifestations of cGVHD, highlighting that skin and joint/fascial involvement were the most frequent, more than 80% of patients, and 15 (18,2%) presented isolated joint contractures secondary to sclerosis without detectable scleroderma/fasciitis. More than 50% (44) of the patients presented at some time during their evolution alteration of the general condition measured by ECOG (Eastern Cooperative Oncology Group). Bone complications appeared in 6 (7.3%) patients in relation to chronic corticotherapy.

Conclusion: Joint/fascial involvement secondary to sclerosis is very frequent in our cohort, with deleterious repercussions on physical function. It is necessary to recognize and evaluate it early with validated scales. The search for new biomarkers associated with fibrosis, the use of advanced imaging techniques and a multidisciplinary approach including physiotherapy programs may help to improve the prognosis of patients with sclerotic -type cGVHD.

Supporting image 1

Supporting image 2


Disclosures: C. Hidalgo, None; C. Roman, None; O. Compan, None; S. Pastor Navarro, None; M. Ibañez, None; B. Miguel, None; M. Sanchez, None; L. Pantoja, None; C. Montilla, None; L. López-Corral, None.

To cite this abstract in AMA style:

Hidalgo C, Roman C, Compan O, Pastor Navarro S, Ibañez M, Miguel B, Sanchez M, Pantoja L, Montilla C, López-Corral L. Clinical Characterization of a Cohort of Patient with Sclerotic-type Chronic Graft-versus-host Disease with Fascial/joint Involvement [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/clinical-characterization-of-a-cohort-of-patient-with-sclerotic-type-chronic-graft-versus-host-disease-with-fascial-joint-involvement/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characterization-of-a-cohort-of-patient-with-sclerotic-type-chronic-graft-versus-host-disease-with-fascial-joint-involvement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology